Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
5
×
boston blog main
life sciences
national blog main
boston top stories
clinical trials
fda
national top stories
eli lilly
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
abbvie
allergan
amgen
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
europe blog main
europe top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
sarepta therapeutics
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
10x genomics
aimmune therapeutics
alkermes
allergy
alprazolam
What
fda
won
approval
drug
friday
medicine
second
therapeutics
therapy
acute
addresses
agency
aimmune
alkermes
allergy
antipsychotic
approved
august
awarded
benefits
betting
billion
bio
biopharma
biotech
busy
causes
caveats
commonly
condition
days
deal
decades
decisions
designed
developed
devices
drugs
duchenne
effect
Language
unset
5
×
Current search:
won���t
×
unset
×
biotech
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More